Login to Your Account

Ark launches drug discovery with RSV compound from Roche

By Shannon Ellis
Staff Writer

Thursday, June 19, 2014
SHANGHAI – Newcomer Ark Biosciences Inc., of Shanghai, has announced its first deal with the acquisition of global rights to Roche AG's respiratory syncytial virus (RSV) drug candidate, AK0529. RSV is one of the most infectious human viruses and the number one cause of death and hospitalization for children younger than 5. There is currently no vaccine or therapeutic drug for RSV infection.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription